A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China

Management of Common Terminology Criteria for Adverse Event (CTCAE) Grades 2-5 nivolumab-related irAEs

Time frame: Up to approximately 48 months

Management of CTCAE Grades 2-5 nivolumab-related AEs

Part 1 and Part 2

Time frame: Up to approximately 48 months

Management of CTCAE Grades 2-5 nivolumab-related SAEs

Part 1 and Part 2

Time frame: Up to approximately 48 months

Distribution of outcomes of CTCAE Grades 2-5 irAEs associated with nivolumab when managed according to the risk management algorithms described in the nivolumab label

Part 1 and Part 2

Time frame: Up to approximately 48 months

Distribution of outcomes of CTCAE Grades 2-5 AEs associated with nivolumab when managed according to the risk management algorithms described in the nivolumab label

Part 1 and Part 2

Time frame: Up to approximately 48 months

Distribution of outcomes of CTCAE Grades 2-5 SAEs associated with nivolumab when managed according to the risk management algorithms described in the nivolumab label

Part 1 and Part 2

Time frame: Up to approximately 48 months

Distribution of treatment patterns of nivolumab in routine oncology practice: Treatment duration

Part 1 and Part 3

Time frame: Up to approximately 48 months

Distribution of treatment patterns of nivolumab in routine oncology practice: Treatment sequencing

Part 1 and Part 3

Time frame: Up to approximately 48 months

Distribution of treatment patterns of nivolumab in routine oncology practice: Reasons for nivolumab discontinuation

Part 1 and Part 3

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Age

Part 1

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Sex

Part 1

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Weight

Part 1

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Height

Part 1

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: BMI

Part 1

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Smoking status

Part 1

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Eastern Cooperative Oncology Group (ECOG) performance status

Part 1

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Comorbidities

Part 1

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Disease history

Part 1

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Treatment history

Part 1

Time frame: Up to approximately 48 months

Distribution of treatment outcomes of NSCLC participants treated with nivolumab from start of nivolumab treatment: overall survival (OS)

Part 1 and Part 3

Time frame: Up to approximately 48 months

Distribution of treatment outcomes of NSCLC participants treated with nivolumab from start of nivolumab treatment: real-world progression free survival (rwPFS)

Part 1 and Part 3

Time frame: Up to approximately 48 months

Distribution of treatment patterns of nivolumab for recurrent squamous cell carcinoma of head and neck (SCCHN)

Part 2 and Part 4

Time frame: Up to approximately 48 months

Distribution of treatment patterns of nivolumab for metastatic SCCHN

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Age

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Sex

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Weight

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Height

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: BMI

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Alcohol consumption

Part 2

Time frame: Up to approximately 48 months

Distribution of demographic characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Human papillomavirus (HPV) status

Part 2

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Smoking status

Part 2

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Eastern Cooperative Oncology Group (ECOG) performance status

Part 2

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Comorbidities

Part 2

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Disease history

Part 2

Time frame: Up to approximately 48 months

Distribution of clinical characteristics of SCCHN participants treated with nivolumab at initiation of nivolumab treatment: Treatment history

Part 2

Time frame: Up to approximately 48 months

Distribution of treatment effectiveness of SCCHN participants treated with nivolumab from the start of nivolumab treatment: OS

Part 2 and Part 4

Time frame: Up to approximately 48 months

Distribution of treatment effectiveness of SCCHN participants treated with nivolumab from the start of nivolumab treatment: rwPFS

Part 2 and Part 4

Time frame: Up to approximately 48 months